title: CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.
abstract: Chlamydia trachomatis is a significant human pathogen with potentially severe disease sequelae in the genital tract, including infertility. A successful vaccine will need to effectively target immunity to the genital mucosa. Intranasal immunisation with cholera toxin (CT) can target immunity to the genital tract, but has the potential to cause neurological side effects. CTA1-DD is a non-toxic potent mucosal adjuvant which combines the enzymatic properties of CT, with a B cell targeting moiety. Here, we demonstrate that intranasal immunisation with CTA1-DD and chlamydial Major Outer Membrane Protein (MOMP) results in the induction of neutralising systemic and mucosal antibodies, and reduces the level of chlamydial shedding following intravaginal challenge with Chlamydia muridarum. Thus, CTA1-DD is an effective adjuvant for vaccine development against Chlamydia trachomatis, and possibly also a range of other genital pathogens.
authors.affiliation: Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane QLD 4059, Australia. kelly.cunningham@qut.edu.au
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Cunningham
authors.forename: Alison J
authors.initials: AJ
authors.lastname: Carey
authors.forename: Nils
authors.initials: N
authors.lastname: Lycke
authors.forename: Peter
authors.initials: P
authors.lastname: Timms
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Beagley
mesh_terms: D000276:Adjuvants, Immunologic / Q000235:genetics / Q000627:therapeutic use*; D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D002690:Chlamydia Infections / Q000150:complications / Q000276:immunology / Q000628:therapy*; D023502:Chlamydia muridarum / Q000276:immunology / Q000472:pathogenicity; D002692:Chlamydia trachomatis / Q000276:immunology* / Q000472:pathogenicity; D002772:Cholera Toxin / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D005835:Genitalia / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D006801:Humans; D007114:Immunization; D007136:Immunoglobulins / Q000097:blood; D007246:Infertility / Q000209:etiology / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D009092:Mucous Membrane / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D018272:Porins / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; C440610:CTA1-DD protein, recombinant; D007136:Immunoglobulins; D018272:Porins; D011993:Recombinant Fusion Proteins; C071677:omp1 protein, Chlamydia trachomatis; D002772:Cholera Toxin